ValuEngine upgraded shares of GTX (NASDAQ:GTXI) from a sell rating to a hold rating in a research report released on Wednesday.

A number of other equities analysts also recently commented on the stock. Stifel Nicolaus initiated coverage on shares of GTX in a research note on Thursday, November 9th. They issued a buy rating for the company. Robert W. Baird initiated coverage on shares of GTX in a research note on Tuesday, November 21st. They issued an outperform rating and a $17.00 price objective for the company. Zacks Investment Research raised shares of GTX from a sell rating to a hold rating in a research note on Wednesday, January 17th. Finally, BidaskClub raised GTX from a buy rating to a strong-buy rating in a research report on Friday, January 26th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $17.00.

GTX (NASDAQ GTXI) opened at $14.39 on Wednesday. GTX has a 12 month low of $2.73 and a 12 month high of $15.81.

GTX (NASDAQ:GTXI) last issued its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). research analysts anticipate that GTX will post -1.61 earnings per share for the current fiscal year.

In other news, insider Jason T. Shackelford sold 3,090 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $35,009.70. Following the transaction, the insider now directly owns 31,111 shares of the company’s stock, valued at $352,487.63. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc Steven Hanover sold 7,309 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $11.33, for a total value of $82,810.97. Following the transaction, the chief executive officer now directly owns 129,990 shares in the company, valued at $1,472,786.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,364 shares of company stock worth $174,074. Insiders own 41.20% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new stake in shares of GTX during the second quarter valued at $124,000. Caxton Corp purchased a new stake in shares of GTX during the third quarter valued at $531,000. Finally, Abingworth LLP purchased a new stake in shares of GTX during the third quarter valued at $2,781,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades GTX (GTXI) to “Hold”” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2018/02/08/valuengine-upgrades-gtx-gtxi-to-hold.html.

GTX Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.